Class Action Lawsuit Filed Against Pacira BioSciences, Investors Urged to Join by March 14, 2025
In a significant legal development for investors, Levi & Korsinsky, LLP has filed a class action lawsuit against Pacira BioSciences, Inc. (NASDAQ: PCRX). This legal action comes as a response to alleged securities fraud that reportedly occurred between August 2, 2023, and August 8, 2024. Investors are being invited to join the lawsuit before the March 14, 2025, deadline.
The Nature of the Lawsuit
This lawsuit aims to recover losses for investors who were adversely impacted by the fraudulent activities connected to the company. The complaint highlights a pivotal moment on August 9, 2024, when Pacira announced unfavorable results from its legal battle against eVenus concerning patent infringement. The decision from the court revealed that Pacira's U.S. Patent No. 11,033,495, which pertains to its flagship product Exparel, was deemed invalid. This finding calls into question the strength and validity of other patents held by Pacira, raising concerns about the potential influx of generic competitors into the market.
As a consequence of this announcement, Pacira’s stock price plummeted from approximately $22.36 per share, prior to the release, to a low of $11.70 the following day—a staggering decline of over 47% in a single trading session.
What Current and Former Investors Should Know
Investors who experienced losses during the class period should act quickly, as they have until March 14, 2025, to request the court to appoint them as lead plaintiffs. Importantly, participation in the lawsuit does not necessitate serving as a lead plaintiff for individuals to be eligible for any potential recovery. The process entails no upfront financial obligations for those joining the lawsuit.
No Costs Involved
According to statements from Levi & Korsinsky, class members who meet the criteria may be entitled to compensation without incurring any out-of-pocket expenses. This legal team, with over two decades of experience, has a strong track record of securing substantial settlements for aggrieved shareholders. They employ a dedicated team of over 70 professionals focused on securities litigation, ensuring that clients receive thorough representation.
Why Choose Levi & Korsinsky
Levi & Korsinsky has established itself as a leader in the field of securities litigation, consistently ranking among the top firms in the United States for handling class actions. The firm has achieved hundreds of millions of dollars in recoveries for its clients and has a reputation for success in high-stakes legal battles. Over the past seven years, it has been featured in the ISS Securities Class Action Services' Top 50 Report, showcasing their expertise in this complex area of law.
Contact Information for Interested Investors
Individuals interested in joining the class action are encouraged to reach out to Joseph E. Levi, Esq. via email at email protected] or call (212) 363-7500 for assistance. Professionals at Levi & Korsinsky stand ready to assist potential class members in understanding their rights and the claims process. To provide additional resources, an online form is available for those wishing to participate in the lawsuit. Interested parties can visit the following link for more information: [Pacira BioSciences Class Action Information.
Conclusion
With significant developments surrounding Pacira BioSciences, the upcoming deadline for individuals to join the class action lawsuit stands as a crucial timeline for investors. Those who have been affected by the recent financial declines and uncertainties surrounding the company's patent litigations are strongly encouraged to explore their options in this legal action.
The Nature of the Lawsuit
This lawsuit aims to recover losses for investors who were adversely impacted by the fraudulent activities connected to the company. The complaint highlights a pivotal moment on August 9, 2024, when Pacira announced unfavorable results from its legal battle against eVenus concerning patent infringement. The decision from the court revealed that Pacira's U.S. Patent No. 11,033,495, which pertains to its flagship product Exparel, was deemed invalid. This finding calls into question the strength and validity of other patents held by Pacira, raising concerns about the potential influx of generic competitors into the market.
As a consequence of this announcement, Pacira’s stock price plummeted from approximately $22.36 per share, prior to the release, to a low of $11.70 the following day—a staggering decline of over 47% in a single trading session.
What Current and Former Investors Should Know
Investors who experienced losses during the class period should act quickly, as they have until March 14, 2025, to request the court to appoint them as lead plaintiffs. Importantly, participation in the lawsuit does not necessitate serving as a lead plaintiff for individuals to be eligible for any potential recovery. The process entails no upfront financial obligations for those joining the lawsuit.
No Costs Involved
According to statements from Levi & Korsinsky, class members who meet the criteria may be entitled to compensation without incurring any out-of-pocket expenses. This legal team, with over two decades of experience, has a strong track record of securing substantial settlements for aggrieved shareholders. They employ a dedicated team of over 70 professionals focused on securities litigation, ensuring that clients receive thorough representation.
Why Choose Levi & Korsinsky
Levi & Korsinsky has established itself as a leader in the field of securities litigation, consistently ranking among the top firms in the United States for handling class actions. The firm has achieved hundreds of millions of dollars in recoveries for its clients and has a reputation for success in high-stakes legal battles. Over the past seven years, it has been featured in the ISS Securities Class Action Services' Top 50 Report, showcasing their expertise in this complex area of law.
Contact Information for Interested Investors
Individuals interested in joining the class action are encouraged to reach out to Joseph E. Levi, Esq. via email at email protected] or call (212) 363-7500 for assistance. Professionals at Levi & Korsinsky stand ready to assist potential class members in understanding their rights and the claims process. To provide additional resources, an online form is available for those wishing to participate in the lawsuit. Interested parties can visit the following link for more information: [Pacira BioSciences Class Action Information.
Conclusion
With significant developments surrounding Pacira BioSciences, the upcoming deadline for individuals to join the class action lawsuit stands as a crucial timeline for investors. Those who have been affected by the recent financial declines and uncertainties surrounding the company's patent litigations are strongly encouraged to explore their options in this legal action.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.